ARVN
Arvinas, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.62
P/S
2.65
EV/EBITDA
-5.77
DCF Value
$-118.79
FCF Yield
-39.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.5%
Operating Margin
-44.0%
Net Margin
-30.8%
ROE
-14.3%
ROA
-11.3%
ROIC
-20.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $9.5M | $-67.4M | $-1.04 |
| FY 2025 | $262.6M | $-80.8M | $-1.28 |
| Q3 2025 | $41.9M | $-35.1M | $-0.48 |
| Q2 2025 | $22.4M | $-61.2M | $-0.84 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.98
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.